Please login to the form below

Not currently logged in
Email:
Password:

eczema

This page shows the latest eczema news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

as eczema) - a chronic skin condition characterised by skin blistering, cracking and often debilitating itching - and is the first targeted biologic drug for this purpose.

Latest news

More from news
Approximately 7 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Embracing digital disruption in pharma Embracing digital disruption in pharma

    HelloSkin is the number one online store for emollients, nutrition supplements, accessories and selected over-the-counter products for people living with psoriasis, eczema, acne and dry skin.

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... Corporate acquisition. Acquisition for $99.25 per share [55%

  • Deal Watch November 2015 Deal Watch November 2015

    The deal includes Protopic (tacrolimus) for severe eczema treatment, skin creams Locoid and Locobase and acne therapy Zineryt (erythromycin/zinc acetate).

  • Interview: Jorge Gallardo, Almirall Interview: Jorge Gallardo, Almirall

    Toctino is a once daily oral treatment for adults with severe chronic hand eczema that does not respond to topical corticosteroids.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics